RE:RE:Denali Therapeutics update"Bioasis has a faster Transcytosis rate and delivers a more significant payload in independently published data."
Have you ever noticed that neither Denali nor any other Bioasis competitor is targeting brain tumours with the transport with monoclonal antibody (MAB) fusion proteins across the BBB like Bioasis is.
Why not?
My guess is that they can't get enough drug across the BBB to efficaciously treat brain tumours without going toxic in the rest of the body. Instead, they're picking LSDs and other diseases where any delivery at all might still produce a commercial drug.
So why does Bioasis have, as our first development programs, the HER2+ and Glioblastoma brain tumour pipeline elements, xB3-001 and xB3-002? Wouldn't you think that all companies would want to take a run at these potential blockbusters?
For the answer, see Mark Day's comment at the top of this post.
jdstox